Cephalexin is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms:, - Respiratory tract infections caused by S. pneumoniae and group A beta-haemolytic streptococci (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.), - Bacterial sinusitis caused by streptococci, S. pneumoniae and S. aureus (methicillin-sensitive only), - Otitis media due to S. pneumoniae, staphylococci,- Skin and soft-tissue infections caused by staphylococci and/or streptococci, - Genitourinary tract infections, including acute prostatitis caused by E. coli, P. mirabilis, and Klebsiella sp.,The effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin is not indicated in these conditions.,NOTE: Appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin. Renal function studies should be performed when indicated.
Tablet Description
Light green size 0 hard gelatin capsules printed "500" on body and " CEP" on cap in black ink
Cephalexin is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms:, - Respiratory tract infections caused by S. pneumoniae and group A beta-haemolytic streptococci (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.), - Bacterial sinusitis caused by streptococci, S. pneumoniae and S. aureus (methicillin-sensitive only), - Otitis media due to S. pneumoniae, staphylococci,- Skin and soft-tissue infections caused by staphylococci and/or streptococci, - Genitourinary tract infections, including acute prostatitis caused by E. coli, P. mirabilis, and Klebsiella sp.,The effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin is not indicated in these conditions.,NOTE: Appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin. Renal function studies should be performed when indicated.
Tablet Description
Light green size 0 hard gelatin capsules printed "500" on body and " CEP" on cap in black ink
Cephalexin is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms:, - Respiratory tract infections caused by S. pneumoniae and group A beta-haemolytic streptococci (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.), - Bacterial sinusitis caused by streptococci, S. pneumoniae and S. aureus (methicillin-sensitive only), - Otitis media due to S. pneumoniae, staphylococci,- Skin and soft-tissue infections caused by staphylococci and/or streptococci, - Genitourinary tract infections, including acute prostatitis caused by E. coli, P. mirabilis, and Klebsiella sp.,The effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin is not indicated in these conditions.,NOTE: Appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin. Renal function studies should be performed when indicated.
Tablet Description
Light green size 0 hard gelatin capsules printed "500" on body and " CEP" on cap in black ink
Cephalexin is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms:, - Respiratory tract infections caused by S. pneumoniae and group A beta-haemolytic streptococci (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.), - Bacterial sinusitis caused by streptococci, S. pneumoniae and S. aureus (methicillin-sensitive only), - Otitis media due to S. pneumoniae, staphylococci,- Skin and soft-tissue infections caused by staphylococci and/or streptococci, - Genitourinary tract infections, including acute prostatitis caused by E. coli, P. mirabilis, and Klebsiella sp.,The effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin is not indicated in these conditions.,NOTE: Appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin. Renal function studies should be performed when indicated.
Tablet Description
Light green size 0 hard gelatin capsules printed "500" on body and " CEP" on cap in black ink
Storage Conditions
Store below 30 degrees Celsius
Additional Information
Generic Name: Cephalexin
PBS Listed: ✔
RPBS: ✘
Strength: 500mg
Dosage: Capsules
Pack Size: 20
Schedule: S4
Shelf Life: 36 Months
Innovator: Keflex®
Warnings
Connecting Care, Simplifying Supply.
At Pharmacor, we bridge the gap between healthcare providers and seamless supply solutions, ensuring care is always within reach.